Intercept's principal drug is Ocaliva® (obeticholic acid), an FDA-approved farnesoid X receptor agonist in the United States and numerous other regions.

Gracell Biotechnologies Inc. has announced that the initial patient in the US has begun treatment in a Phase 1b/2 clinical trial for it's foremost candidate, GC012F, targeting patients with recurrent or resistant multiple myeloma.

Adverum Biotechnologies has released early findings on aflibercept protein activity from its ongoing Phase 2 LUNA study.

Two patients have been administered the initial dosage of SMART101, an allogeneic cell therapy created from donor mobilized peripheral blood stem cells which have been converted into T-cell progenitors utilizing the ProTcell treatment platform by Smart Immune.

Ionis declared encouraging preliminary findings from Phase 3 trial of Olezarsen in patients suffering from familial chylomicronemia syndrome.

YS Biopharma Co., Ltd., pledged to discovery, develop, produce, and supply innovative vaccines and therapeutic biologics for infectious illnesses and cancer.

Remegen's Novel Medication Telitacicept (RC18) Achieves Favorable Phase III Outcomes, Applied for a Secondary Use in Managing Rheumatoid Arthritis.

Mesentech recently revealed that its Phase 1 trial has begun, and the initial patients have already received their doses of MES1022.

Elpiscience Biopharmaceuticals has revealed that the initial patient has received a dose in a Phase 1 clinical study of the anti-LILRB2 monoclonal antibody ES009 in Australia.

Edgewise Therapeutics, Inc., has initiated the participation induction for GRAND CANYON, an international principal examination of EDG-5506 designed for Becker patients.

Arcturus Therapeutics and the Cystic Fibrosis Foundation continue partnership to further the development of ARCT-032, an experimental mRNA therapy for Cystic Fibrosis.

Inozyme Pharma reports encouraging preliminary results from ongoing INZ-701 phase 1/2 studies in adults with ENPP1 and ABCC6 (PXE) deficiencies.